Latest research on Imatinib

Imatinib is a small molecule kinase inhibitor used to treat certain types of cancer. It is currently marketed by Novartis as Gleevec (USA) or Glivec (Europe/Australia) as its mesylate salt, imatinib mesilate (INN). It is occasionally referred to as CGP57148B or STI571 (especially in older publications). It is used in treating chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GISTs) and a number of other malignancies. It is the first member of a new class of agents that act by inhibiting particular tyrosine kinase enzymes, instead of non-specifically inhibiting rapidly dividing cells.

Latest findings

Imatinib (IM) is a selective TK inhibitor (TKI) and presents one of the current first line treatments for CML [23, 24]. [source, 2016]
For example, the U.S. pharmacy retail prices of NovoSeven (5 mg/1 kit), Gleevec (400 mg/30 tablets) were over $9,200 and $7,000 in 2013, respectively [7]. [source, 2016]
These orphan drugs are Imiglucerase, sapropterin dihydrochloride, recombinant coagulation Factor VIII, coagulation factor VIIa, human coagulation Factor VIII, human prothrombin complex concentrate, bosentan, Iloprost, ambrisentan, recombinant human Growth hormone, Busulfan, teniposide, Mitoxantrone, Imatinib, Dasatinib, nilotinib, meisoindigo, Arsenious Acid, homoharringtonine, rituximab, sorafenib, Danazol, Riluzole and poractant alfa. [source, 2016]
Among those drugs that are unaffordable, NovoSeven is the most unaffordable, followed by Rituximab, Sorafenib tosylate, Imatinib and Bosentan. [source, 2016]
The oral inhibitor of M-CSF receptor 27 reduced the arthritis progression by inactivating the TYROSINE kinase, which can also be achieved by Imatinib mesylate (Glivec®; Novartis International AG, Basel, Switzerland). [source, 2016]
We found that several known anticancer drugs can regulate cancer cell metabolism pathways, such as caldribine, Sirolimus, everolimus, temSirolimus and Imatinib. [source, 2016]
Based on c-Kit gene mutant status, drugs that inhibit c-Kit, such as Imatinib [39], sorafenib [40], and Sunitinib [41], may provide better results [42]. [source, 2016]
The initiating breakthrough for this type of approach was the development of Gleevec® (Imatinib), a BCR–ABL oncogene inhibitor that achieves 98% Complete hematologic response and 86% Complete cytogenetic response in patients with early stage chronic myeloid leukemia (CML). [source, 2016]
Adjuvant Imatinib, a TYROSINE kinase inhibitor, is useful in select cases of GIST based on risk of recurrence [5–8]. [source, 2016]
TYROSINE kinase inhibitors such as Imatinib have revolutionized the treatment of CML. [source, 2016]